GeneDx Holdings Corp. reiterated earnings guidance for the year 2023 and 2025. The continuing operations of GeneDx, excluding revenues and direct costs from the now discontinued Legacy Sema4 diagnostic testing business, are expected to generate revenues between $205 million to $220 million for full year 2023.

The company expects to turn profitable in 2025.